Advanced Search:
Equity Index Forex Crypto Commodity

GMAB - Genmab

$29.26  -0.48 (-1.61%)

Updated: 03:13 May 5, 2024 EST

Next Hour's AI Forecast

99.57%

Avg. Accuracy (AI)

$29.26

Next Session's AI Forecast

97.08%

Avg. Accuracy (AI)

$29.83

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

$29.42

Genmab's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

GENMAB - HISTORICAL DATA 6M

  • Last price

    $ 29.26

  • Daily change

    $ -0.48

  • Previous Close

    $ 29.74

  • Last Updated

    03:13 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.37 -0.14 0.14 -0.02 -0.11

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
4.44 1.99 1.74 1.7 1.57

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
65.5% 69.47% 62.55% 49.52%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
29.16 2.17% 28.54 -2.53% 29.28 -1.78% 29.81

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.68 39.76 1.16 40.48

Genmab Technical Analysis News

Genmab

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 2286
Description

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Corporate Governance

Genmab A/S’s ISS Governance QualityScore as of May 1, 2024 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 9.

GENMAB'S HOLDERS RANK

List of holders with stock participation in Genmab.

Holder Rank Holder Shares Date Reported % Out Value